Logo image
2277 Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis
Journal article   Open access   Peer reviewed

2277 Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis

Andrew Hannaford, Nathan Pavey, Mehdi Van den Bos, Nimesh Geevasinga, Parvathi Menon, Jeremy Shefner, Matthew Kiernan and Steve Vucic
BMJ neurology open, Vol.4(Suppl 1), pp.A3-A3
08/2022

Abstract

Abstracts
ObjectiveThe diagnosis of amyotrophic lateral sclerosis (ALS) remains problematic, with current diagnostic criteria (revised El Escorial [rEEC] and Awaji) being complex and prone to error. Consequently, the diagnostic utility of the recently proposed Gold Coast criteria was determined in ALS.MethodsWe retrospectively reviewed 506 patients (302 males, 204 females) to compare the diagnostic accuracy of the Gold Coast criteria to that of the Awaji and rEEC criteria (defined by the proportion of patients categorized as definite, probable, or possible ALS) in accordance with standards of reporting of diagnostic accuracy criteria.ResultsThe sensitivity of Gold Coast criteria (92%, 95% confidence interval [CI] = 88.7–94.6%) was comparable to that of Awaji (90.3%, 95% CI = 86.69–93.2%) and rEEC (88.6, 95% CI = 84.8–91.7%) criteria. Additionally, the Gold Coast criteria sensitivity was maintained across different subgroups, defined by site of onset, disease duration, and functional disability. In atypical ALS phenotypes, the Gold Coast criteria exhibited greater sensitivity and specificity.InterpretationThe present study established the diagnostic utility of the Gold Coast criteria in ALS, with benefits evident in bulbar and limb onset disease patients, as well as atypical phenotypes. The Gold Coast criteria should be considered in clinical practice and therapeutic trials.
url
https://doi.org/10.1136/bmjno-2022-ANZAN.8View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image